This strategy was tested in the randomized PLATO trial (NCT01995513).[36][Level of evidence B1] Apalutamide, an androgen receptor antagonist, was tested in patients with clinically nonmetastatic, castration-resistant prostate cancer (defined as PSA doubling time 10 months while undergoing androgen deprivation therapy).[37] In the trial, 1,207 men were randomly assigned in a 2:1 ratio to receive either daily apalutamide (240 mg PO) or a placebo
Earlier investigations within the STEP initiative were confined to durations not exceeding 68 weeks
has received research grants to the institution from 89Bio, Gilead, Hanmi, Intercept, Madrigal, Merck, Novo Nordisk and Salix
Semaglutide is administered via subcutaneous injection once per week using a pre-filled pen
2015;309(8):R795804
The enhanced efficacy of tirzepatide likely stems from its dual mechanism: The addition of GIP receptor activation appears to provide synergistic benefits, potentially through: Enhanced insulin secretion Direct effects on adipose tissue Complementary appetite regulation pathways The Next Frontier: Triple Agonist Research If dual agonism improves upon single agonism, what about triple agonism
